Phase 1 Depression and Anxiety Trial, Recruiting NCT02994433 Sponsor: Washington University School of Medicine Condition: Depression and Anxiety
Back to Depression And Anxiety

Phase 1 Depression and Anxiety Trial, Recruiting

NCT02994433
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 65 years of age
  • People who are right-handed
  • For the healthy volunteer (control) group: People who do not have major depression, confirmed by scoring 7 or below on a standard depression rating scale, and who have no personal history of depression based on reported history and medical records
  • For the treatment-resistant depression group: People who have major depression confirmed by scoring 17 or above on a standard depression rating scale, and whose medical records show that at least 3 to 4 antidepressant treatments at adequate doses and durations have not worked, including at least one treatment during the current depressive episode
  • People with a good command of the English language

Who may not be able to join:

  • People who have been diagnosed with another significant mental health condition (other than major depression for the depression group), as confirmed by medical records and a structured clinical interview
  • People with known neurological or serious medical conditions, including dementia, stroke, brain injury, Parkinson's disease, brain tumors, multiple sclerosis, seizure disorders, or severe heart or lung disease
  • People currently taking any medication that acts on the central nervous system, as assessed by the study investigator
  • People with a known condition that affects how the body processes or removes drugs, such as kidney or liver disease, as assessed by the study investigator
  • People who are left-handed
  • People who are not suitable for MRI scans, for example due to a history of claustrophobia or having metal implants in the body (as determined by an MRI screening tool)
  • For the control group only: People currently using any psychiatric medications, antidepressants, or prescription or non-prescription drugs or herbal products intended to treat depression or anxiety
  • People with a history of substance dependence or misuse within the past 12 months, based on reported history or a urine drug screen
  • People who are able to become pregnant and are not using effective contraception
  • People for whom nitrous oxide (the study drug) would be medically unsuitable, including those with: a collapsed lung (pneumothorax), a bowel obstruction, a blockage in the middle ear, raised pressure in the skull, a chronic deficiency in vitamin B12 or folate being treated with supplements, current pregnancy, or those who are breastfeeding
  • People who are not able to provide informed consent
  • People who, in the investigators' judgment, may face safety risks or difficulties participating for any other reason — for example, living more than 100 miles from the clinic

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Charles R Conway, MD, Washington University School of Medicine

Phone: 314-362-2463

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
27 January 2017
Est. completion
30 April 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Comparison of functional connectivity between default mode network of treatment-resistant depressed and non-depressed participants; Comparison of functional connectivity between affective network of treatment-resistant depressed and non-depressed participants; Comparison of functional connectivity between cognitive control network of treatment-resistant depressed and non-depressed participants; Comparison of functional connectivity between dorsal nexus of treatment-resistant depressed and non-depressed participants

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov